- Home
- SBR vs HELP Comparison
SBR vs HELP Comparison
Compare SBR & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBR | HELP |
|---|---|---|
| Founded | 1982 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 862.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SBR | HELP |
|---|---|---|
| Price | $68.00 | $8.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $41.56 |
| AVG Volume (30 Days) | 16.6K | ★ 1.5M |
| Earning Date | 11-11-2026 | 11-16-2026 |
| Dividend Yield | ★ 6.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $65.31 | $3.76 |
| 52 Week High | $79.86 | $15.15 |
Technical Indicators
Market Signals| Indicator | SBR | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 27.69 | 32.27 |
| Support Level | N/A | $4.41 |
| Resistance Level | $73.50 | $14.75 |
| Average True Range (ATR) | 1.15 | 0.92 |
| MACD | -0.49 | -0.16 |
| Stochastic Oscillator | 0.00 | 10.53 |
Price Performance
Historical ComparisonAbout SBR Sabine Royalty Trust
Sabine Royalty Trust formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.